Cancer Therapy

Pro-Pharmaceuticals doses patients with Davanat in Phase II biliary cancer trial

Published in Clinical Oncology Week, February 19th, 2007

Pro-Pharmaceuticals, Inc. (PRW), a developer of novel carbohydrate compounds, announced the dosing of patients in its Phase II, first line, biliary cancer trial. The Phase II trial is an open-label, multi-center trial of Davanat with 5-Fluorouracil (5-FU) to treat patients with advanced bile duct and gall bladder cancer.

"Our excellent Phase I/II results show Davanat, when co-administered with 5-FU, stabilized the disease and improved the quality of life for many of the end-stage cancer patients," said David Platt, PhD, president and chief executive officer, Pro-Pharmaceuticals, Inc. "When we combine the very positive results from those trials, with the data expected...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Oncology Week

Source: Clinical Oncology Week (2007-02-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry